Search Results - yibin+kang

10 Results Sort By:

Utilization of Human Recombinant Tinagl1 Protein in Inhibiting Triple-negative Breast Cancer Progression and Metastasis

Utilization of human recombinant Tinagl1 protein in inhibiting triple-negative-breast cancer progression and metastasis Princeton Docket # 19-3526Researchers in Princeton University’s Department of Molecular Biology have developed the human recombinant protein Tubulointerstitial nephritis antigen like-1 (Tinagl1) as a promising treatment for triple-negative...
Published: 9/6/2022   |   Inventor(s): Yibin Kang, Minhong Shen
Keywords(s):  
Category(s): Biotechnology/Pharmaceuticals

MiRNAs as Novel Therapeutics and Non-invasive Biomarkers for Bone Metastasis

Princeton Docket # 12-2807 Researchers in the Molecular Biology Department at Princeton University have discovered a group of miRNAs as novel therapeutics for bone metastasis. Through a series of in vitro and in vivo experiments, five distinctive miRNAs have been identified as inhibitors of osteoclast differentiation. Further, systemic treatment...
Published: 3/30/2022   |   Inventor(s): Yibin Kang, Brian Ell
Keywords(s): biomarker/diagnostic, Biotechnology/Pharmaceuticals, cancer/oncology, drug discovery, miRNA, therapeutic
Category(s): Biotechnology/Pharmaceuticals, Medical Devices/Diagnostics

EGFR Inhibitors as Therapeutic Agents for Breast Cancer Bone Metastasis

Princeton University Invention # 09-2509 The involvement of the EGFR signaling pathway in bone metastasis has been implicated by a number of studies. However, the therapeutic significance by targeting EGFR signaling in the tumor-stroma interface has not been evaluated. Researchers in the Molecular Biology Department at Princeton...
Published: 3/30/2022   |   Inventor(s): Yibin Kang, Xin Lu
Keywords(s): antibody, cancer/oncology, therapeutic
Category(s): Biotechnology/Pharmaceuticals

Template Guided DNA

Princeton University Invention # 09-2521 Researchers in Ecology and Evolutionary Biology and Molecular Biology, Princeton University, have described a new process based on the natural biological mechanism of RNA-guided DNA recombination as discovered and reported in their recent publication, Nowacki et al. Nature 2008 January ¹. The process...
Published: 3/30/2022   |   Inventor(s): Laura Landweber, Mariusz Nowacki, Wenwen Fang, Yibin Kang
Keywords(s):  
Category(s): Biotechnology/Pharmaceuticals

VCAM1 and VLA4 as Therapeutic Targets for Anti-Tumor and Anti Metastatic Therapy

Princeton University Invention # 09-2550 In breast cancer patients, disseminated tumor cells from the primary site can remain in a dormant state in the secondary organ for a long period before starting to grow into life-threatening metastasis. However, the molecular understanding of this process is still very limited. Researchers in Molecular...
Published: 3/30/2022   |   Inventor(s): Yibin Kang, Xin Lu
Keywords(s):  
Category(s): Biotechnology/Pharmaceuticals

miR-200 Family and miR194/192 Cluster of miRNAs in Cancer Progression and Metastasis

Princeton University Invention # 09-2551 Over 90% of cancer-related deaths are due to the metastatic spread of primary tumor cells to distant vital organs. Epithelial-mesenchymal transition (EMT) is a key cellular process through which tumor cells gain the ability to migrate and invade into their surrounding tissue. The reverse process, (MET),...
Published: 3/30/2022   |   Inventor(s): Yibin Kang, Manav Korpal
Keywords(s):  
Category(s): Biotechnology/Pharmaceuticals

A Cell Line and Mouse Model for Studying Pathological TGFß Signaling during Cancer Progression and Metastasis in vivo

Princeton Invention # 07-2351 Cancer metastasis requires the intricate interactions between cancer cells and the host tissue microenvironment. Although TGFb signaling pathway has been implicated in breast cancer metastasis to bone and other target organs, the temporal-spatial requirement and the in vivo dynamics of TGFb signaling...
Published: 3/30/2022   |   Inventor(s): Yibin Kang
Keywords(s): drug discovery, life science research tools, platform technology
Category(s): Biotechnology/Pharmaceuticals

Metadherin: Therapeutic Target for Treating Primary and Metastatic Cancer and Combating Chemoresistance

Princeton Docket # 07-2399 Researchers in the Molecular Biology Department at Princeton University have identified a recurrent 8q22 genomic gain in poor-prognosis human breast cancers, which harbors the metastasis gene Metadherin (MTDH). Genomic gain of 8q22 elevates expression of MTDH, which is overexpressed in more than 40% of breast cancers...
Published: 9/6/2022   |   Inventor(s): Yibin Kang, Guohong Hu
Keywords(s): Biotechnology/Pharmaceuticals, cancer/oncology, drug target, life science venture/early
Category(s): Medical Devices/Diagnostics, Biotechnology/Pharmaceuticals

Novel Therapeutics for Cancer Metastasis

Princeton Docket # 11-2691-1 Using various in vitro and in vivo xenograft model systems and clinical samples, researchers in the department of molecular biology, Princeton University have validated a stage-specific functional role of the miR-200 family to tumor progression. Current studies suggest that the miR-200 family may hinder an early step...
Published: 3/30/2022   |   Inventor(s): Yibin Kang, Manav Korpal
Keywords(s): biomarker/diagnostic, cancer/oncology, drug target
Category(s): Medical Devices/Diagnostics, Biotechnology/Pharmaceuticals

Jagged1, a marker and therapeutic target for breast cancer bone metastasis

Princeton Docket # 11-2669 Although several molecular contributors of bone metastasis have been identified, effective therapies still await a more comprehensive understanding of the complex molecular and cellular networks of tumor stromal interactions in bone metastasis. Researchers in the Department of Molecular Biology, Princeton University...
Published: 3/30/2022   |   Inventor(s): Yibin Kang, Nilay Sethi
Keywords(s): biomarker/diagnostic, cancer/oncology, drug target, life science venture/early
Category(s): Medical Devices/Diagnostics, Biotechnology/Pharmaceuticals